AMAG - AMAG Pharmaceuticals, Inc.
| Previous Close | 20.650 |
| Open | 20.600 |
| Bid | 20.600 x 900 |
| Ask | 20.650 x 800 |
| Day's Range | 20.550 - 20.800 |
| 52 Week Range | 11.930 - 26.100 |
| Volume | 101,240 |
| Avg. Volume | 563,430 |
| Market Cap | 713.587M |
| Beta | 0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•4 days ago
AMAG Pharmaceuticals Partners With Emmy-Nominated Actress Cheryl Hines and Dr. Marla Shapiro to Start a Conversation About an Often Unrecognized and Untreated Medical Condition, Painful Sex Due to Menopause
AMAG Pharmaceuticals, Inc. (AMAG) today announced that together with Emmy®-nominated actress Cheryl Hines and leading family medicine and menopause expert, Marla Shapiro, MD, it is launching an integrated campaign to start an open dialogue about painful sex due to menopause, a topic that is often not talked about among post-menopausal women and their healthcare providers. Vulvar and vaginal atrophy, or VVA, affects approximately 50 percent of postmenopausal women in the United States, and painful sex is one of the potential symptoms.1 Unlike more commonly known symptoms of menopause, such as hot flashes, many women are not aware that painful sex is associated with menopause.
- PR Newswire•11 days ago
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results
Vyleesi™ New Tradename for Bremelanotide PDUFA Target Action Date of March 23, 2019 for Vyleesi Teleconference and Webcast to be held on September 13, 2018 CRANBURY, N.J. , Sept. 13, 2018 /PRNewswire/ ...
- GlobeNewswire•18 days ago
AMAG Pharmaceuticals Pays Off $475 Million of Senior Secured Notes
AMAG Pharmaceuticals, Inc. (AMAG) today announced that it has redeemed $475 million of its outstanding 7.875% senior notes, using the proceeds from the sale of Cord Blood Registry®, which closed on August 6, 2018. “Through the payment of our senior notes, which eliminates nearly $40 million in annual cash interest expense, as well as the early retirement of the $320 million term loan in May 2017, we have dramatically improved our financial profile,” said Ted Myles, AMAG’s chief financial officer. AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs.
- GlobeNewswire•last month
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Aug. 23, 2018-- AMAG Pharmaceuticals, Inc. today announced that company management will participate in the following investor conferences:. B. Riley FBR Healthcare Conference Tuesday, September ...
- GlobeNewswire•last month
Factors of Influence in 2018, Key Indicators and Opportunity within AMAG Pharmaceuticals, Pier 1 Imports, Gogo, IDT, Axalta Coating, and Sprouts Farmers Market — New Research Emphasizes Economic Growth
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMAG ...
- PR Newswire•2 months ago
California Cryobank And Cord Blood Registry Combine To Create A Leading Life Sciences Platform
LOS ANGELES , Aug. 6, 2018 /PRNewswire/ -- California Cryobank , the world's leading donor sperm and donor egg bank, announced today that it has been acquired by GI Partners, a private equity investment ...
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Completes Divestiture of Cord Blood Registry®
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has closed the previously announced divestiture of Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. The purchase price is subject to customary purchase price adjustments with respect to working capital, cash, indebtedness and transaction expenses as previously disclosed. “Completing the divestiture of CBR is an important step in the successful execution of AMAG’s strategic plan which focuses on growing and diversifying our pharmaceutical business,” said William Heiden, president and chief executive officer at AMAG.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of Brian Robinson, M.D. as senior vice president, medical affairs, reporting into Julie Krop, M.D., chief medical officer and executive vice president, development.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Achieved 12% revenue growth and record quarterly sales. Raising full year revenue and adjusted EBITDA guidance for pharmaceutical products. Conference call scheduled for 8:00 a.m. ET today.
- ACCESSWIRE•2 months ago
AMAG Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:00 AM Eastern ...
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Thursday, August 2, 2018 at 8:00 a.m. ET
WALTHAM, Mass., July 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that its second quarter 2018 financial results will be released on Thursday, August 2, 2018 before the U.S. financial markets ...
- PR Newswire•3 months ago
California Cryobank And Cord Blood Registry To Be Combined By GI Partners To Create A Leading Life Sciences Platform
LOS ANGELES, June 15, 2018 /PRNewswire/ -- California Cryobank, the world's leading donor sperm and donor egg bank, announced today that it has signed a definitive agreement for GI Partners, a private equity investment firm, to acquire the company from leading healthcare investors Longitude Capital and NovaQuest Capital. In a separate transaction announced today, GI Partners has also entered into a definitive agreement with AMAG Pharmaceuticals, Inc. (AMAG) to acquire Cord Blood Registry (CBR), the world's largest stem cell collection and storage company.
- ACCESSWIRE•3 months ago
Initiating Free Research Reports on ArQule and Three Other Biotech Equities
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
- ACCESSWIRE•5 months ago
Wired News – Auris Medical Reported Publication Related to AM-111 in Peer-Reviewed Scientific Journal Hearing Research
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Auris Medical Holding AG (NASDAQ: EARS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EARS as the Company's latest news hit the wire. On May 04, 2018, the Switzerland-based biopharmaceutical Company announced that the article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, the Company's investigational treatment for acute inner ear hearing loss, was published in Hearing Research, one of the leading journals in the otorhinolaryngology field. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published.